SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Steven Przybyla was appointed as President of Ispire Technology Inc., effective August 11, 2026, in addition to his existing roles as Chief Legal Officer and Secretary. The appointment strengthens the company's U.S.-based leadership and investor communications capabilities.
View raw filing on EDGAR →The 6-K discloses the appointment of Ms. Shanyu Chang as Chief Financial Officer effective August 17, 2026, following the resignation of Mr. Huaguang Huang. While both a departure and appointment occur, the principal disclosed action is the appointment of a named executive to a C-suite role (CFO), which is the forward-looking governance event. The filing includes biographical information establishing Ms. Chang's qualifications and confirming no conflicts of interest, consistent with exec_appointment disclosure practice.
View raw filing on EDGAR →The Board elected Ret. Lt. Gen. Sean Gainey to serve on the Board and its Nominating and Corporate Governance Committee on August 13, 2026. This is a clear appointment of a director to the Board, which is a material governance event affecting the composition of the registrant's leadership. The disclosure includes his background, compensation arrangements, and standard indemnification agreement, all consistent with a director appointment disclosure.
View raw filing on EDGAR →Constantine Petropoulos was appointed Senior Vice President and Chief Financial Officer effective August 12, 2026. While the disclosure also includes a compensatory arrangement (salary increase from $357,000 to $425,000 and a stock option grant of 25,000 shares), the principal disclosed action is the appointment of an executive to a material C-suite role (CFO). The appointment of a CFO is a significant governance event affecting investor assessment of the company's leadership and financial oversight.
View raw filing on EDGAR →Jonathan Gutoski was appointed Chief Financial Officer of Edible Garden AG effective August 17, 2026, replacing Kostas Dafoulas who resigned as Interim CFO on August 14, 2026. While the section discloses both a departure and an appointment, the principal disclosed action centers on the appointment of a named executive officer to a key financial leadership role. The disclosure includes Gutoski's background, compensation ($220,000 base salary plus $10,000 signing bonus and up to 25% discretionary bonus), and confirms no related-party arrangements or conflicts of interest.
View raw filing on EDGAR →The Company entered into a Non-Employee Director Agreement with Ximing Huang, formalizing his three-year term as Chairman and CEO. The agreement establishes his executive role and governance position within the Company.
View raw filing on EDGAR →The filing discloses the appointment of Oscar Suarez as an independent director and Audit Committee Chair, effective August 17, 2026. The Board increased from five to six members to accommodate this appointment. Suarez brings over four decades of accounting, tax, and governance experience from Arthur Andersen, KPMG, and EY, making this a material governance event affecting the composition and oversight structure of the Board.
View raw filing on EDGAR →The filing discloses the appointment of Carol L. Brosgart, MD to Cocrystal Pharma's Board of Directors, effective August 12, 2026. The press release emphasizes her extensive experience in antiviral drug development, FDA approvals, and prior roles at major pharmaceutical companies (Gilead, Tobira), making this a material governance event affecting board composition and strategic direction at a clinical-stage biotech company.
View raw filing on EDGAR →The exhibit announces the appointment of Caroline Levy, a veteran Wall Street consumer analyst with 30+ years of experience and current board member of Celsius Holdings, to Prenetics' Board of Directors as an independent director, with concurrent service on the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee. This is a material governance event affecting board composition and oversight structure.
View raw filing on EDGAR →The Board of Directors appointed Sarah Watterson as a Class III independent director effective August 17, 2026, expanding the Board from nine to ten members. The appointment includes compensatory arrangements consisting of an annual cash retainer of $75,000 and an RSU grant of $215,000.
View raw filing on EDGAR →The 6-K discloses the appointment of Andrea Lupo Lanzara as a Class III director of Scorpio Tankers Inc., effective August 17, 2026, to fill a vacancy created by the resignation of Marianne Økland. While both a departure and an appointment occur, the principal disclosed action is the appointment of a new director to the board, making exec_appointment the appropriate classification. Board-level director appointments are material to investors' assessment of governance and leadership.
View raw filing on EDGAR →The filing discloses the appointment of Kevan P. Krysler as an independent Class I director effective August 13, 2026, with assignment to the Audit Committee. The prose centers on the principal action of a person taking a governance role, supported by his extensive background as CFO of publicly traded Everpure (NYSE: P) and VMware, plus 18 years at KPMG as a partner. This is a material governance event affecting board composition and audit oversight.
View raw filing on EDGAR →The disclosure centers on the election of Pamela J. Tomczik to the Board of Directors on August 11, 2026, with detailed background on her qualifications and prior roles at Target Corporation, Thomson Reuters, and other companies. While the section also mentions Peter C. Wallace's retirement, the principal action disclosed is Tomczik's appointment as a director, making this an exec_appointment event. Board composition changes are material to investors assessing governance and oversight.
View raw filing on EDGAR →Robert J. Maines was appointed as Executive Vice President – Chief Operations Officer, effective August 17, 2026, with a salary increase to $440,000 and an equity-based incentive target of $225,000.
View raw filing on EDGAR →Nader Pasdar was appointed as Executive Vice President – Chief Business Officer of Farmer Mac, effective August 17, 2026, bringing 25+ years of experience in agricultural finance and capital markets, including prior service as CEO of Rabo Securities.
View raw filing on EDGAR →Nchacha Etta was appointed Executive Vice President and Chief Financial Officer of U.S. Physical Therapy, effective September 1, 2026. The appointment includes a comprehensive employment agreement specifying a two-year term, $625,000 annual base salary, equity grants totaling approximately $750,000, severance benefits of two years' base compensation upon termination without cause, and change-of-control benefits of $283,333.
View raw filing on EDGAR →Cable One's Board appointed Heather McCallion as Chief Operating Officer, effective August 24, 2026. McCallion brings 25+ years of executive leadership experience and will be responsible for operational strategy, sales, customer experience, and digital transformation across all regions.
View raw filing on EDGAR →Joshua Pinto, Ph.D., was appointed Chief Executive Officer effective August 14, 2026, and also appointed as a Class III director, succeeding Paul L. Berns who transitioned to Executive Chairperson.
View raw filing on EDGAR →The filing discloses both the departure of Raymond Barrios as Co-CEO and director (effective August 10, 2026) and the appointment of Eric Hall as Co-CEO and director/Chairman (effective August 11, 2026). While both events occur, the principal disclosed action centers on the appointment of a new Co-CEO and Chairman, making exec_appointment the most salient classification. The appointment of a Co-CEO and Chairman to lead the company is material to investors' assessment of the registrant's governance and leadership.
View raw filing on EDGAR →The filing discloses both the resignation of Raymond Barrios as President (effective August 10, 2026) and the appointment of Eric Hall as President (effective August 11, 2026). While both events are disclosed, the principal action emphasized is the appointment of Eric Hall to the President role, with his background and existing CEO position detailed. The appointment of a new President is material to investors assessing leadership continuity and governance.
View raw filing on EDGAR →The filing discloses the appointment of Robert W. Gunning as principal accounting officer effective August 10, 2026, succeeding Louise Kooij. While the disclosure also mentions Kooij's departure, the principal action disclosed is Gunning's appointment to the role, supported by detailed biographical information, compensation terms (base salary $375,000, 30% bonus target, RSU and option grants), and offer letter terms. This is a material executive appointment at a pharmaceutical company.
View raw filing on EDGAR →Byrna Technologies appointed retired U.S. Army Brigadier General Rose Lopez Keravuori to its Board of Directors effective August 10, 2026, and assigned her to a newly formed Enterprise Risk Management Committee. Concurrently, director Emily Rooney resigned, and the company dissolved its Product Safety Committee as part of a board governance restructuring.
View raw filing on EDGAR →The filing discloses the appointment of Wellington J. Reiter as an independent director to fill a newly created fifth board seat, effective August 11, 2026, along with his appointment to the Audit Committee. While compensatory arrangements (RSU grants totaling 210,045 units) are also disclosed, the principal action is the director appointment itself. This is material to investors as it affects board composition and governance structure.
View raw filing on EDGAR →Jason F. Simone was appointed Chief Financial Officer effective August 10, 2026. The disclosure centers on the appointment of an officer to a named executive position, with background on his tenure and prior roles at the company. No compensatory arrangements are being entered into in connection with the appointment, and no departure of a prior CFO is mentioned, making this a straightforward executive appointment event.
View raw filing on EDGAR →The filing discloses the appointment of Seth Cohen to the Board of Directors effective August 12, 2026, with the Board increasing from four to five directors. While the disclosure also mentions Cohen's standard director compensation and indemnification agreement, the principal action is his appointment to the Board and Compensation Committee. This is a material governance event for a newly public company (S-1 effective July 15, 2026) adding a director with significant federal nuclear policy expertise.
View raw filing on EDGAR →The 6-K discloses the appointment of Ms. Zhiqin Lu as an Independent Director effective August 14, 2026, following the resignation of Mr. Ow Kian Jing Dennis. While both a departure and appointment occur, the principal disclosed action is the appointment of a replacement director to the Board and Audit Committee. The appointment of an independent director to a public company's board is material to investors' assessment of governance and oversight.
View raw filing on EDGAR →The Board appointed Christy J. Oliger as a Class II director effective September 1, 2026, with assignment to two Board committees. Ms. Oliger brings 30+ years of biopharmaceutical commercial and operating experience, including senior roles at Genentech leading multi-billion-dollar product portfolios, which is material to the company's advancement toward commercialization.
View raw filing on EDGAR →Michael Smith, the Company's Chairman, has been appointed as interim Chief Executive Officer and Chief Financial Officer, replacing Samuel Morrow who transitions to a non-executive director role. This is a material executive appointment affecting the Company's top leadership structure and operational control during the interim period while the Company seeks permanent candidates for these critical roles.
View raw filing on EDGAR →Jill Windrum was appointed as Chief Accounting Officer and Deputy Chief Financial Officer effective August 31, 2026, replacing Brian LaRose as principal accounting officer. This is a material executive appointment to a senior financial leadership role. While the disclosure also includes compensatory arrangements (base salary of $400,000, target bonus of 50%, and sign-on equity awards of $400,000), the principal disclosed action is the appointment itself, making exec_appointment the most salient classification.
View raw filing on EDGAR →The announcement discloses the appointment of Mr. Ying Kang as Assistant Vice President of Finance effective August 13, 2026, with assumption of full oversight of the Finance Department starting August 21, 2026, reporting directly to the CEO. While the exhibit also mentions Dan Xie's departure from the CFO role, the principal disclosed action is Ying Kang's appointment to a senior finance leadership position. This is material as it represents a change in the registrant's financial leadership structure.
View raw filing on EDGAR →Jason O'Byrne was appointed as Chief Financial Officer, principal financial officer, and principal accounting officer of Olema Pharmaceuticals, effective August 11, 2026, approved by the Board on July 28, 2026. The appointment includes compensatory arrangements including a base salary of $545,000, 45% bonus target, $350,000 sign-on bonus, and a 650,000-share option grant. The CEO emphasized O'Byrne's extensive finance and capital markets leadership experience at major biotechnology firms will be essential as the company approaches pivotal clinical data and commercial launch.
View raw filing on EDGAR →Sprinklr appointed Jordi Ribas, Ph.D., a senior Microsoft executive with 26+ years of experience in Search & AI, to its Board of Directors as a Class II director effective August 17, 2026, following Board approval on August 10, 2026. Dr. Ribas was assigned to the Nominating and Corporate Governance Committee and Strategy Committee.
View raw filing on EDGAR →Evolution Metals & Technologies Corp. appointed General Thomas A. Bussiere (ret.) as an independent director and member of the Audit, Compensation, and Nominating and Corporate Governance Committees, effective August 13, 2026. General Bussiere brings 40 years of Air Force leadership experience, including command of Air Force Global Strike Command overseeing 33,000+ personnel and multi-billion-dollar programs.
View raw filing on EDGAR →The filing discloses the appointment of Lee McIntire as Chief Executive Officer effective August 11, 2026. While the disclosure also includes compensatory details (base salary of $750,000, annual bonus eligibility, $15,000 monthly housing allowance, and a $3,000,000 RSU grant), the principal action is the appointment of a named executive to a C-suite role. The appointment of a CEO is a material governance event affecting investor assessment of company leadership.
View raw filing on EDGAR →Scott Scheirman was appointed to Oportun's Board of Directors effective August 11, 2026, as a Class I director and Chair of the Audit & Risk Committee, bringing extensive executive and board experience from major financial services companies including prior CEO and CFO roles.
View raw filing on EDGAR →The filing announces three executive appointments: Phill Wood as CEO of the newly formed International Division (effective immediately), Rafael Carrasco as CEO of North America Division (joined 3 August 2026), and Matt Jochim as Group Chief Transformation Officer (effective 7 September 2026). These are material leadership changes affecting the Company's executive structure and strategic execution, particularly the appointment of a new Group Chief Transformation Officer to the Executive Leadership Team reporting directly to the CEO.
View raw filing on EDGAR →Kenneth J. Giacobbe was appointed to Carpenter Technology's Board of Directors as a Class III director, effective August 11, 2026. The appointment was accompanied by the concurrent departures of Howard Yu (resignation effective October 6, 2026) and Colleen Pritchett (not seeking re-election), with Giacobbe's extensive CFO experience at Howmet Aerospace making the board composition change material to investors.
View raw filing on EDGAR →Keith Demmings has been elected to Moody's Board of Directors, effective November 1, 2026. Demmings is the President and CEO of Assurant with nearly three decades of leadership experience and extensive global operating and insurance expertise. His director compensation arrangement includes a $120,000 annual retainer plus a $230,000 RSU award.
View raw filing on EDGAR →John Gerdin was appointed to American Fusion's Board of Directors as an Independent Director and Strategic Advisor, effective August 10–11, 2026. The appointment is structured through a Consulting Services Agreement with JRMS Consulting LLC and brings significant international finance and capital markets expertise to the company's leadership.
View raw filing on EDGAR →The filing discloses the appointment of Jeffrey F. DiModica to the Board of Directors effective August 10, 2026, and his appointment to the Investment Committee. While the section also mentions Jeffrey G. Dishner's resignation, the principal disclosed action centers on DiModica's appointment to the Board. DiModica's extensive background as President since 2014 and his prior directorship (2009–2014) make this a material governance event affecting board composition and oversight.
View raw filing on EDGAR →The exhibit announces the appointment of Peter Rawlins as Chief Financial Officer effective August 26, 2026, replacing interim CFO David Allen. While the exhibit also reports Q2 2026 financial results, the principal disclosed action is the executive appointment. The CFO role is material to a development-stage company executing a major refinery construction project, and Rawlins' extensive mining finance and capital markets experience is directly relevant to the company's funding and project execution priorities.
View raw filing on EDGAR →The filing discloses the appointment of Scott Colangelo to the Board of Directors effective August 11, 2026, and his concurrent appointment to the Audit Committee. The principal disclosed action is a person taking a role as director, which is the core event under Item 5.02(d). While the disclosure mentions standard director compensation arrangements, the focus is on the appointment itself rather than compensation terms, making exec_appointment the most salient classification.
View raw filing on EDGAR →Anthony Aliquo was appointed Chief Accounting Officer and principal accounting officer effective August 10, 2026, representing a material promotion from Vice President, Controller. While the filing also discloses that Fred Ahlholm ceased serving as principal accounting officer (a secondary change), the principal disclosed action centers on Aliquo's appointment to a named executive officer role. The appointment is accompanied by salary and bonus increases, confirming its significance.
View raw filing on EDGAR →The filing discloses two executive events: Nancy Hawthorne's retirement and resignation as Trustee and Chairperson, and Patrick Coyne's election to Chairperson. While both a departure and an appointment occur, the prose centers on the appointment of Coyne to the Chairperson position as the forward-looking action taken by the Board in response to Hawthorne's departure. The appointment of a new Chairperson is material to investors as it represents a change in board leadership.
View raw filing on EDGAR →Lawrence Burian was elected as a Class II Director to the Board of Directors of Cinemark Holdings, Inc., effective immediately, to fill a vacancy. The appointment includes standard non-employee director compensation of a $95,000 base retainer and an annual restricted stock grant of $175,000.
View raw filing on EDGAR →The filing discloses the appointment of Jonathan Peri, Ph.D., J.D. as an independent director to Citius Oncology's Board, effective August 10, 2026, expanding the Board to nine members. The Board determined Dr. Peri qualifies as independent under Nasdaq listing standards and will be compensated under the Company's director compensation program. This is a clear executive/director appointment event under Item 5.02(d).
View raw filing on EDGAR →The Board appointed Aaron Alt as an independent director effective August 14, 2026, and also appointed him to the Audit and Finance Committee. This is a clear executive appointment event. While the disclosure mentions that Mr. Alt will participate in standard non-employee director compensation arrangements, the principal disclosed action is the appointment itself, not a new or modified compensation arrangement, making exec_appointment the most salient classification.
View raw filing on EDGAR →The filing discloses both a departure (Riley McCormack's resignation from the Board) and an appointment (Paul Carreiro's election to the Board on the same date). While both events occurred, the appointment is the principal forward-looking action—Carreiro was elected to fill the vacancy and will serve until the next shareholder meeting. The appointment of a new director to the Board is material to investors' assessment of governance and leadership continuity.
View raw filing on EDGAR →John C. Reed, M.D., Ph.D., a highly accomplished pharmaceutical executive with significant experience at Johnson & Johnson, Sanofi, and Roche, was appointed to Madrigal's Board of Directors effective August 11, 2026, expanding the Board from eight to nine members. Dr. Reed will serve on the Science and Technology Committee and receive an annual cash retainer of $50,000, committee fee of $10,000, and an equity grant valued at $675,000.
View raw filing on EDGAR →The filing discloses the appointment of Keith C. Costello as Executive Vice President and Chief Operating Officer, effective August 17, 2026. While the disclosure also includes compensatory arrangements (base salary of $460,000, equity awards of 150,000 stock options and 150,000 RSUs, and severance provisions), the principal action is the appointment of a named executive officer to a senior operational role. The appointment of a COO is material to investors as it affects the company's leadership structure and operational oversight.
View raw filing on EDGAR →